Drug Discovery Featured Articles & Applications

  1. GLP-1 And Addiction: Mechanism, Missteps, And What Comes Next 5/4/2026

    Evidence suggests GLP-1R agonists may influence reward pathways and craving, raising important questions for addiction research and drug development.

  2. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.

  3. GLP-1 Agonists In Addiction: Rationale And Drug Development 4/24/2026

    GLP-1 receptor agonists represent a scientifically credible and potentially consequential avenue in addiction medicine.

  4. Why Rare Cancers Are Often Left Behind In Drug Discovery 4/23/2026

    Combining advances in AI with continued investment in rare cancer research could help bring new treatment options to patients who currently have very few.

  5. Why Cell And Gene Therapies Break After Early Success 4/22/2026

    The field has largely solved how to trigger biology, and yet, many programs still fail because what happens cannot be sustained, controlled, or directed over time.

  6. AI: The Inflection Point In Retinal Drug Discovery, Development, And Delivery 4/21/2026

    AI won’t replace clinical or biological insight; instead pairing AI with scientific expertise will sharpen and accelerate retinal therapeutic development.

  7. AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy 4/20/2026

    By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.

  8. Antibiotic-Resistant STIs: Men's Health Is Entering A New Era Of Therapeutic Risk 4/20/2026

    What was once a reliably treatable infection is increasingly defined by resistance patterns that limit therapeutic options and complicate management.

  9. If AI Can't Read Your Science, Investors Won't Either 4/17/2026

    As investors deploy AI to screen thousands of deals at once, life sciences founders who keep their story locked behind NDAs risk never making it past the first automated filter.

  10. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.